Tom Miller is a successful engineer and serial entrepreneur. He’s been responsible for innovative chemical research and applications development in both industry and medicine for more than 35 years. Tom founded IC-MedTech in 2004 and is committed to finding new, less toxic treatments for cancer and other diseases. The company has developed intellectual property for small molecules as primary and pan-adjuvant therapies treating cancer, inflammatory and genetic diseases.
Dr. Coutts brings over 37 years experience in the pharmaceutical/biotech industry employing both small molecule and biologic approaches to drug development. Dr. Coutts has expertise evaluating technologies and business plans and providing technical diligence for development and licensing. His primary expertise is in chemistry and biochemistry, with experience in allergy, inflammatory and autoimmune diseases and cancer.
Dr. Panetta is the former Chief Scientific Officer at the Polycystic Kidney Disease Foundation where she directed the foundations’s research strategy and was the key architect of the Foundation’s Accelerating Treatments to Patients (ATP) research initiative. Dr. Panetta is cofounder and former Chief Scientific Officer of InnoCentive, a global leader in crowdsourcing innovation problems worldwide. Dr. Panetta has over 20 years of experience in drug discovery research and development at Eli Lilly and Company, including generating IP for the prevention of bone loss and resorption, treatment of diabetes, and neuroprotection with an emphasis on stroke and Alzheimer’s Disease. Dr. Panetta's early research efforts led to the discovery of two clinical candidates: tibenelast for asthma and tazofelone for inflammatory bowel disease. Over her career, she has authored more than 88 publications and abstracts, has given over 65 invited lectures and has 33 granted US patents.
Mr. Terry Harstad is the Founder and President of LifeScience Media in Orange County, CA. LifeScience Media develops custom e-marketing and e-education programs for medical device and pharmaceutical companies.